Stock Price Quote

LYKA LABS LTD.

NSE : LYKALABSBSE : 500259ISIN CODE : INE933A01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE121.65-3.3 (-2.64 %)
PREV CLOSE ( ) 124.95
OPEN PRICE ( ) 125.25
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3796
TODAY'S LOW / HIGH ( )118.55 125.25
52 WK LOW / HIGH ( )99.95 175.95
NSE121.10-3.6 (-2.89 %)
PREV CLOSE( ) 124.70
OPEN PRICE ( ) 126.55
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 133998
TODAY'S LOW / HIGH( ) 118.00 126.55
52 WK LOW / HIGH ( )97.9 176.59
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 29-12 1976
Management Info
Babulal Jain - Chairman Kunal N Gandhi - Managing Director
Registered Office

Address 4801/B & 4802/A,G I D C Industrial Estate, ,
Ankleshwar,
Gujarat-393002

Phone 02646-221422 /220549

Email companysecretary@lykalabs.com

Website www.lykalabs.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,L B S Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

05Feb Lyka Labs informs about integrated fil
Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated..
04Feb Lyka Labs informs about outcome of boa
Lyka Labs has informed that the Board of Directors of the Company at its..
24Jan Lyka Labs informs about scheme of amal
In furtherance to earlier intimation dated 26th October, 2024, wherein t..
30Dec Lyka Labs informs about board meeting
Lyka Labs has informed that a meeting of the Board of Directors of the C..
26Oct Lyka Labs informs about scheme of amal
Lyka Labs has informed that in furtherance to Outcome of the Board Meeti..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit26.99-22.6999999999999
Gross Profit 35.9 -9.32999999999994
Operating Profit 59.6162.07
Net Sales 329.211063.96

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Ajanta Pharma (BSE)
peergroup  2558.40 (2.61%)
M.Cap ( in Cr)31957.51
Coral Laboratories (BSE)
peergroup  807.60 (8.54%)
M.Cap ( in Cr)288.52
Vimta Labs (BSE)
peergroup  1119.70 (3.91%)
M.Cap ( in Cr)2488.29
Mercury Laboratories (BSE)
peergroup  849.00 (3.78%)
M.Cap ( in Cr)101.88
Aarti Drugs (BSE)
peergroup  410.85 (7.20%)
M.Cap ( in Cr)3749.83

Shareholding Pattern

PROMOTERS 58.1%
NON-INSTITUTION 41.07%
FI/BANKS/INSURANCE 0.28%
MUTUAL FUNDS/UTI 0.01%
GOVERNMENT 0%
FII 0%

About Lyka Labs Ltd.

Lyka Labs Ltd. was incorporated in the year 1976. Its today's share price is 121.65. Its current market capitalisation stands at Rs 434.17 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1063.96 Cr and Total Income of Rs.1080.44 Cr. The company's management includes Shekhar R Singh, Prashant Godha, Kunal N Gandhi, Shashil P Mendonsa, Yogesh Shah, Dhara Shah, Neeraj Golas, Babulal Jain.

It is listed on the BSE with a BSE Code of 500259 , NSE with an NSE Symbol of LYKALABS and ISIN of INE933A01014. It's Registered office is at 4801/B & 4802/A,G I D C Industrial Estate, Ankleshwar-393002, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are D Kothary & Co, MA Parikh & Co, Mehta Chokshi & Shah

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.